Schweiz / Suisse / Svizzera / Switzerland

Veterinary certificate for the exportation of *in vitro produced* (IVP) embryos from Switzerland to New Zealand

Part I: Details of dispatched consignment

I.1. Consignor
Name:
Address:

Tel:

I.2. Certificate reference number*:

I.3. a. Central competent authority:
Federal Food Safety and Veterinary Office FSVO

I.3. b. Cantonal competent authority:

I.4. Consignee
Name:
Address:

I.5. Country of origin: **Switzerland**
ISO Code: **CH**

I.6. Country of destination: **New Zealand**
ISO Code: **NZ**

I.7. Place of origin
Name:
Address:

I.8. Place of loading:

I.9. Expected border post:

I.10. Means of transport (if available):
Aeroplane ☐ Ship ☐ Railway wagon ☐
Road vehicle ☐ Other ☐

Identification:

I.11. Temperature of product:
Ambient ☐ Chilled ☐ Frozen ☐

I.12. Identification of container/seal number:

I.13. Commodities intended for use as:
Breeding/rearing ☐ Wildlife management ☐ Other ☐

I.14. Total number of packages:

I.15. Identification of commodities[1]:

Dam/Sir

Species	Donor Identity	Approval number of the team	Sex	Date(s) of collection[2]	Straw identification[2]	Date(s) of AI[3]

1) If necessary, extra tables can be attached as annex by the consignor and should be approved and stamped by the cantonal competent authority.
2) Applicable for Dams only
3) Applicable for Sirs only

* Indicated by the cantonal competent authority.

Switzerland	Bovine Embryo (IVP)
II. Sanitary information	Certificate reference number*:

Part II: Sanitary information

I, the undersigned official veterinarian, certify that …

1) The germplasm herein described complies/y with the relevant Swiss legislation and requirements which have been recognized as equivalent to New Zealand legislation and requirements as prescribed in the Agreement between New Zealand and the Swiss Confederation on Sanitary Measures Applicable to Trade in Live Animals and Animal Products. Specifically, in accordance with
   - Swiss Ordinance on the import, transit and export of animals and animal products in trade with third countries (SR 916.443.10)
   - Swiss Ordinance on Animal Disease (SR 916.401).

2) Eligibility

   The consignment consists of frozen, *in vitro* produced (IVP) embryos from the Bovinae subfamily.

3) Additional health attestation

   A) The animal products are eligible for trade within the European Union without restriction.

   B) All laboratory samples required by this veterinary certificate have been collected, processed, and stored in accordance with the WOAH's recommendations or as described in Approved Diagnostic Tests, Vaccines, Treatments and Post-Arrival Testing Laboratories for Animal Import Health Standards, MPI-STD-SAA, found here: https://www.mpi.govt.nz/dmsdocument/2040/.

   C) The oocytes for the production of IVP embryos for export to New Zealand have been collected from live donor cows or heifers via ovum pick-up (OPU) or equivalent techniques. The oocytes have not been collected from slaughterhouses.

   D) The embryos herein described were collected, processed and stored in conformity with the provisions of the WOAH terrestrial Animal Code Chapters on *Collection and Processing of In Vitro Produced Embryos from Livestock and Equids*, the recommendations in the IETS Manual and where applicable, with the WOAH code Chapter on *Collection and Processing of Micromanipulated Oocytes or Embryos from Livestock and Horses*

   E) **Bovine herpes virus 1.1 and 1.2a (Infectious Bovine Rhinotracheitis/Infectious Pustular Vulvovaginitis, IBR/IPV)**

   either ☐ a) The semen used to produce the embryos for export to New Zealand meets the requirements for BHV-1.1 and 1.2a in an agreed certificate between New Zealand and an approved country; and

   either ☐ (i) At the time of collection of oocytes for the production of embryos for export to New Zealand, the country of export was free from BHV 1.1 and BHV 1.2a in accordance with the *WOAH Code;*

   or ☐ (ii) The oocytes for production of IVP embryos for export to New Zealand were derived from donors that were resident in a herd maintained free from BHV-1.1 and 1.2a,

   or ☐ (iii) The oocyte donor was subjected to an agent detection test listed in MPI-STD-SAA for BHV-1.1 and 1.2a on vaginal swab sample or blood sample obtained on the day of oocyte collection, with negative result,

   or ☐ (iv) The oocyte donor was subjected to a serological test for BHV-1.1 and 1.2a with a test listed in MPI-STD-SAA on the day of oocyte collection and at least 21 days later, with negative results,

   or ☐ (v) A sample of oocytes (viable or non-viable) or follicular fluid from the day of collection was subjected to an agent detection test listed in MPI-STD-SAA for BHV 1.1 and 1.2a, with negative results;

   or ☐ b) A sample of the resultant IVP embryos (viable or non-viable) from the batch for export or culture medium taken immediately prior to embryo storage were subjected to an agent detection test listed in MPI-STD-SAA for BHV 1.1 and 1.2a, with negative results.

   F) **Bovine herpes virus 5 (BHV-5)**

   The semen used to produce the embryos for export to New Zealand meets the requirements for BHV-5 in the agreed certificate between New Zealand and an approved country;

   and

   The oocyte donor's herd of residence have had no cases of BHV-5 (suspected or diagnosed) in the year prior to collection for export to New Zealand.

   G) **For Bovine Viral Diarrhea genotype 2 (BVDV2)**

   either ☐ At the time of germplasm collection for export to New Zealand the exporting country was free from BVDV2;

   or ☐ A sample of the from the embryo collection for export to New Zealand was tested for BVDV2 in accordance with MPI-STD-SAA, with negative results;

* Indicated by the cantonal competent authority.

Switzerland	Bovine Embryo (IVP)
II. Sanitary information	Certificate reference number*:

or ☐ A sample of oocytes (viable or non-viable) or follicular fluid from the day of collection was subjected to an agent detection test listed in MPI-STD-SAA for BVDV2, with negative results, and the semen used to produce the embryos must meet the requirements for BVDV2 in this IHS;

or ☐ The embryo donor was tested for persistent BVDV2 infection using an agent detection test listed in MPI-STD-SAA, with negative results; and

(i) The semen used to produce the embryo for export to New Zealand meets the requirements for BVDV2 of a veterinary certificate agreed between New Zealand and an approved country.

(ii) The embryo donor has not been vaccinated against BVDV2 within the 30 days prior to embryo or oocyte collection

(iii) The embryo donor was tested for acute BVDV2 infection in accordance with MPI-STD-SAA, with negative results, in one of the following ways:

either ☐ with an antigen capture ELISA immediately prior to an isolation period of at least 21 days before collection for New Zealand. Isolation excluded bovine animals that were not tested negative for BVDV2 upon entry to the collection herd, and throughout isolation the herd showed no clinical signs consistent with BVDV2;

or ☐ with virus isolation test within 48 hours of collection for New Zealand;

or ☐ serologically between 2 weeks and 6 months after collection.

H) **Foot and mouth disease (FMD)**

either ☐ a) The oocyte donor was resident for at least the 3 months before embryo collection in a country or zone that is free from FMD without vaccination in accordance with the WOAH Code;

or ☐ b) The oocyte donors had been continuously residing for at least three months before oocyte collection in an FMD-free country or zone that has freedom from FMD with vaccination in accordance with the WOAH Code, and:

(i) The semen used to produce the embryos for export to New Zealand meets the requirements for FMD in an agreed certficate; and the oocyte donors were either;

either ☐ Subjected, not less than 21 days after collection, to an MPI recommended serological test, with negative result;

or ☐ Vaccinated at least twice against FMD between one and six months before oocyte collection;

and

(ii) The embryo collection, processing and storage facility in the exporting country used during the preparation of an export consignment to New Zealand was approved by a Chief Technical Officer (CTO).

I) **Lumpy skin disease (LSD)**

either ☐ The embryo or oocyte donor was resident for 6 months prior to germplasm collection in a country or zone that is free from LSD as defined by the *WOAH Code;*

or ☐ The embryo donor was resident in an establishment that was free of clinical evidence of LSD during a period from at least 60 days prior to commencement, until 28 days after conclusion of germplasm collection for export to New Zealand; and

(i) The semen used to produce the embryos for export to New Zealand meets the requirements for LSD in an agreed certificate between New Zealand and an approved country, and

(ii) The donor was tested with an agent detection test listed in MPI-STD-SAA with negative results on a blood sample collected on the date of collection; and was

either ☐ 1. Unvaccinated and subjected to a serological test listed in MPI-STD-SAA for LSD on the day of embryo collection and 21 days later, with negative results;

or ☐ 2. Regularly vaccinated against LSD according to manufacturer's instructions, the first vaccination administered at least 60 days before the first embryo collection and demonstrated to have antibodies against LSDV at least 30 days after vaccination

or ☐ A sample from the embryo collection for export to New Zealand was tested for LSDV using with an agent detection test in accordance with MPI-STD-SAA, with negative results.

J) **Rift Valley fever virus (RVF)**

* Indicated by the cantonal competent authority.

Switzerland	Bovine Embryo (IVP)
II. Sanitary information	Certificate reference number*:

either ☐ The embryo or oocyte donor was resident, for at least the 30 days prior to, and during germplasm collection for export to New Zealand in a country or zone that was free from RVF in accordance with the *WOAH Code;*

or ☐ The donor showed no sign of RVF within the period from 14 days prior to and 14 days following germplasm collection; and:

either ☐ i) The donor was vaccinated against RVF in accordance with *MPI-STD-SAA* at least 14 days prior to collection;

or ☐ ii) The donor was demonstrated to be seropositive on the day of collection with a test listed in *MPI-STD-SAA;*

or ☐ iii) Testing of paired samples with a test listed in *MPI-STD-SAA* demonstrated that seroconversion did not occur between germplasm collection and 14 days after.

or ☐ iv) In the case of IVP embryos, the semen used to produce the embryos for export to New Zealand meets the requirements for RVF in an agreed certificate with an approved country.

K) **Brucella abortus, B. melitensis and B. suis**

The semen used to produce the embryos for export to New Zealand satisfies the requirements for Brucella in an agreed certificate between New Zealand and an approved country.

L) **For Q Fever (*Coxiella burnetii*)**

either ☐ An aliquot of germplasm from each collection for export to New Zealand was tested for Q fever with a test listed in MPI-STD-SAA, with negative results;

or ☐ The oocyte donor has never been confirmed positive for Q fever; AND;

either ☐ (i) The donor was subjected to a serological test listed in MPI-STD-SAA for Q fever, on a sample collected between 21 and 120 days after each germplasm collection for export to New Zealand, with negative result

or ☐ (ii) Within the 6 month period before or after germplasm collection for export to New Zealand, but before export, the embryo collection herd was tested for Q fever, using a test listed in MPI-STD-SAA, with negative results. The Q fever test was:

1 performed on either the whole herd or a random sample of at least 60 animals (whichever is the lesser number); and

2. the herd was isolated for the period between embryo collection and diagnostic sampling.

M) ***Leptospira interrogans* serovar Hardjoprajitno (leptospirosis)**

either ☐ Antibiotics were added during the embryo processing in accordance with MPI-STD-SAA

or ☐ The semen used to produce the embryos for export to New Zealand meets the requirements for Leptospirosis in this IHS;

and

The embryo donor was tested for *L interrogans* serovar Hardjoprajitno in accordance with MPI-STD-SAA, with negative results;

or ☐ The embryos were tested with a test listed in MPI-STD-SAA, with negative results.

N) ***Mycobacterium tuberculosis* (bovine tuberculosis)**

The embryo donor was from an embryo collection herd that was free at the time of collection for export to New Zealand from bovine tuberculosis in accordance with the Competent Authority of the exporting country; and the donor was:

either ☐ From a country or zone free from bovine tuberculosis;

or ☐ Subjected to a test listed in MPI-STD-SAA for bovine tuberculosis during the period between 30 days prior to and 12 months after embryo/oocyte collection for export to New Zealand, with negative results.

O) **Contagious Bovine Pleuropneumonia (CBPP)**

Switzerland	Bovine Embryo (IVP)
II. Sanitary information	Certificate reference number*:

either ☐ The *in vitro* derived embryos described were derived from donors that have been continuously resident in a country that is recognized as free from CBPP;

or ☐ The *in vitro* derived embryos herein described were derived from donors that

(i) have not been vaccinated against CBPP; and

(ii) were kept since birth, or for at least the 6 months prior to commencement until conclusion of germplasm collection for export to New Zealand in establishments where no case of CBPP has been reported, and which are not situated in a CBPP infected zone, as defined by the WOAH Code; and

(iii) were serologically tested for CBPP, using a test listed in MPI-STD-SAA on two occasions 21 to 30 days apart, with the last test within 14 days prior to germplasm collection for export to New Zealand, with negative results.

P) **For Mycoplasma bovis**

either ☐ Embryos were processed in accordance with the recommendations of the WOAH Code, with the modifications indicated in MPI-STD-SAA;

or ☐ Each embryo collection for export to New Zealand was tested with a validated test for M. bovis in accordance with MPI-STD-SAA, with negative results;

Notes

Part I:

Box I.7.: Place of origin shall correspond to the approved embryo collection team listed in accordance with Article III.8-9 in the Technical Directions for zoosanitary regulation of the practice of embryo transfer and the collection of oocytes from cattle, horses, sheep/goats and swine (TW über Seuchenpolizeiliche Anforderungen an die Durchführung des Embryotransfers und die Gewinnung von Eizellen von Rindern, Pferden, Schafen/Ziegen und Schweinen, 08/09/2008) on the FSVO website:

https://www.blv.admin.ch/dam/blv/de/dokumente/tiere/nutztierhaltung/tw-durchfuehrung-embryonentransfers%20.pdf.download.pdf/TW_Gewinnung_Embryonen_Eizellen_D_2008.pdf

Part III:

The signature and the stamp must be in a different colour of that of the printing.

Switzerland	Bovine Embryo (IVP)
II. Signature ☐	Certificate reference number*:

Part III: Signature

Official Veterinarian

Full name and address: Official position:

Date: Stamp and signature:

* Indicated by the cantonal competent authority.